S100A9 and metabolic dysfunction-associated steatotic liver disease: Similar to the results of mRNA microarray in NAFLD tissue samples, the expression levels of CCR2, CXCR2, NCF2, S100A9, S100A12 were found to be significantly upregulated in cells treated with FFA (Fig. 9A–E).